Compare GSK plc (GSK) vs Trade Desk Inc (TTD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Trade Desk Inc — how do they compare? GSK plc trades at $46.65 (market cap $91.88B), while Trade Desk Inc trades at $12.02 (market cap $5.83B). The key difference: GSK plc is far larger — about 15.8× Trade Desk Inc's market cap, and GSK plc pays a 3.9% dividend while Trade Desk Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and Trade Desk Inc for 72 Days on average.
| GSK | TTD | |
|---|---|---|
Market Cap | $91.88B | $5.83B |
Volume | 7,730,529 | 15,864,392 |
Sector | Health | Media |
52-Week High | $61.18 | $54.13 |
52-Week Low | $43.24 | $11.92 |
Typical Hold Time | 93 Days | 72 Days |
Enterprise Value | $111.88B | $4.78B |
Dividend Yield | 3.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.45, down 1.21% with bearish technical signals. The company shows strong fundamentals with revenue growth to $32.67B in 2025 and consistent earnings beats. Valuation metrics appear reasonable with P/E of 14.89 and EV/EBITDA of 8.75. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for long-term growth despite near-term technical weakness.
GSK presents a mixed outlook with strong profitability and pipeline expansion offset by technical bearishness and HIV patent concerns. The company's 29.73% ROE and recent earnings outperformance support investment appeal, while the bearish moving average signal and competitive pressures warrant caution. Analyst consensus leans hold with 55% neutral rating, suggesting balanced risk-reward for long-term investors.
The Trade Desk (TTD) trades at $12.08, down 0.12% on the day and showing bearish technical signals with mixed earnings performance. The company maintains strong profitability with 76.9% gross margins and 15.4% ROE, though revenue growth has slowed to 3% in 2026 projections. Recent news highlights competitive pressures from Amazon and Alphabet, with the stock down significantly from its 2024 peak.
While TTD's valuation appears attractive with low P/E and P/S ratios, investors face headwinds from slowing growth and intense competition. The consensus price target of $14.72 suggests moderate upside potential, but near-term catalysts appear limited as the company navigates market share challenges and workforce reductions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Trade Desk Inc
The Trade Desk Inc is engaged in providing a technology platform for ad buyers. Through its cloud-based platform ad buyers can create, manage, and optimize data-driven digital advertising campaigns across ad formats and channels, including display, video, audio, in-app, native and social, on a multitude of devices. Its products include Data Management Platform, Cross-Device Targeting, Video Advertising, Mobile Advertising, and others.
Read more on TTD →
